Literature DB >> 34950394

Cryptococcal Meningoencephalitis During Convalescence From Severe COVID-19 Pneumonia.

Dharani Rohit Thota1, Bappaditya Ray1, Mirza Hasan2, Kartavya Sharma1.   

Abstract

Invasive cryptococcal infection in a previously immunocompetent patient complicating coronavirus disease 2019 (COVID-19) pneumonia has not been described before. In this report, a 76-year-old woman survived a bout of respiratory failure from severe COVID-19 pneumonia, during which she received remdesivir, convalescent plasma, corticosteroids, and tocilizumab. Soon after discharge, she developed acute encephalopathy and multifocal ischemic strokes. CSF and blood cultures were positive for Cryptococcus neoformans. Cryptococcal meningoencephalitis should be considered in the differential diagnosis of encephalopathy in a patient with COVID-19. Treatment with high-dose steroids and tocilizumab may be predisposing factors.
© The Author(s) 2021.

Entities:  

Keywords:  COVID-19; Cryptococcus; central nervous system infections; ischemic stroke; meningoencephalitis; tocilizumab

Year:  2021        PMID: 34950394      PMCID: PMC8689527          DOI: 10.1177/19418744211009766

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  11 in total

1.  Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.

Authors:  D L Goldman; S C Lee; A J Mednick; L Montella; A Casadevall
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Detected SARS-CoV-2 in Ascitic Fluid Followed by Cryptococcemia: a Case Report.

Authors:  Victor C Passarelli; Ana H Perosa; Luciano Kleber de Souza Luna; Danielle D Conte; Oliver A Nascimento; Jaquelina Ota-Arakaki; Nancy Bellei
Journal:  SN Compr Clin Med       Date:  2020-10-08

Review 3.  Glucocorticoids and invasive fungal infections.

Authors:  Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

4.  Cryptococcal infections in non-HIV-infected patients.

Authors:  Peter G Pappas
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

5.  Invasive fungal diseases during COVID-19: We should be prepared.

Authors:  J-P Gangneux; M-E Bougnoux; E Dannaoui; M Cornet; J R Zahar
Journal:  J Mycol Med       Date:  2020-04-06       Impact factor: 2.391

6.  Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project).

Authors:  M T Montagna; G Caggiano; G Lovero; O De Giglio; C Coretti; T Cuna; R Iatta; M Giglio; L Dalfino; F Bruno; F Puntillo
Journal:  Infection       Date:  2013-03-06       Impact factor: 3.553

7.  Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

Authors:  Spinello Antinori; Cecilia Bonazzetti; Guido Gubertini; Amedeo Capetti; Cristina Pagani; Valentina Morena; Sara Rimoldi; Laura Galimberti; Piercarlo Sarzi-Puttini; Anna Lisa Ridolfo
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

8.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

9.  Late onset infectious complications and safety of tocilizumab in the management of COVID-19.

Authors:  Natasha N Pettit; Cynthia T Nguyen; Gökhan M Mutlu; David Wu; Lucas Kimmig; David Pitrak; Kenneth Pursell
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

View more
  6 in total

Review 1.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

2.  Fatal case of disseminated cryptococcal infection and meningoencephalitis in the setting of prolonged glucocorticoid use in a Covid-19 positive patient.

Authors:  Krupa Karnik; Yuexiu Wu; Samantha Ruddy; Bladimir Quijano-Rondan; Carl Urban; Glenn Turett; Lok Yung; Nishant Prasad; James Yoon; Sorana Segal-Maurer
Journal:  IDCases       Date:  2022-01-06

3.  Missed opportunities to identify cryptococcosis in COVID-19 patients: a case report and literature review.

Authors:  Daniel B Chastain; Andrés F Henao-Martínez; Austin C Dykes; Gregory M Steele; Laura Leigh Stoudenmire; Geren M Thomas; Vanessa Kung; Carlos Franco-Paredes
Journal:  Ther Adv Infect Dis       Date:  2022-01-15

4.  Pulmonary cryptococcosis after recovery from COVID-19 in an immunocompetent patient: A rare case report.

Authors:  Hye Sook Choi
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

5.  Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study.

Authors:  Daniel B Chastain; Vanessa M Kung; Sahand Golpayegany; Brittany T Jackson; Carlos Franco-Paredes; Lilian Vargas Barahona; George R Thompson; Andrés F Henao-Martínez
Journal:  Mycoses       Date:  2022-06-19       Impact factor: 4.931

Review 6.  COVID-19-associated Cryptococcus infection (CACI): a review of literature and clinical pearls.

Authors:  Dinesh Regalla; Mollie VanNatta; Mohammad Alam; Alexandre E Malek
Journal:  Infection       Date:  2022-03-24       Impact factor: 7.455

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.